These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14501983)

  • 21. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
    Riou França L; Launois R; Le Lay K; Aegerter P; Bouhassira M; Meshaka P; Guidet B
    Int J Technol Assess Health Care; 2006; 22(1):101-8. PubMed ID: 16673686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Kalenka A
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698-9; author reply 1699-70. PubMed ID: 15273924
    [No Abstract]   [Full Text] [Related]  

  • 23. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
    Chalfin DB; Teres D; Rapoport J
    Crit Care Med; 2003 Jan; 31(1):306-8. PubMed ID: 12545034
    [No Abstract]   [Full Text] [Related]  

  • 24. An economic evaluation of activated protein C treatment for severe sepsis.
    Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
    N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A word of warning about economic evaluations].
    de Solà-Morales O; Pons JM
    Gac Sanit; 2004; 18(6):486; author reply 487-8. PubMed ID: 15625049
    [No Abstract]   [Full Text] [Related]  

  • 26. Should health care money in South Africa be spent on drotrecogin alfa?
    Taylor B; Burns D; van de Wal BW; MBewu T; Keeton GR
    S Afr Med J; 2003 Jul; 93(7):500-1. PubMed ID: 12939917
    [No Abstract]   [Full Text] [Related]  

  • 27. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
    Hjelmgren J; Persson U; Tennvall GR
    Am J Ther; 2005; 12(5):425-30. PubMed ID: 16148428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
    Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
    Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economic burden of sepsis in Austria.
    Schmid A; Schneider H
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
    [No Abstract]   [Full Text] [Related]  

  • 33. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical aspects of treatment with drotrecogin alfa (activated).
    Camporota L; Wyncoll D
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S7. PubMed ID: 18269694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes.
    Higgins TL; Steingrub JS; Tereso GJ; Tidswell MA; McGee WT
    J Intensive Care Med; 2005; 20(6):339-45. PubMed ID: 16280407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacist intervention in activated protein C therapy for severe sepsis: influence on health and economic outcomes.
    Chan AL; Hsieh HJ; Lin SJ
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):229-35. PubMed ID: 19356388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Activated protein C, coagulation, inflammation and treatment of severe sepsis].
    Ott A
    Ned Tijdschr Geneeskd; 2001 Nov; 145(45):2196-7. PubMed ID: 11727624
    [No Abstract]   [Full Text] [Related]  

  • 39. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.